Showing posts with label rituxan. Show all posts
Showing posts with label rituxan. Show all posts

Wednesday, December 18, 2013

Proof that target therapy has come in to change things in cancers!

1.Combining Ibrutinib with R-CHOP is not only feasible but yield 100% response in Diffuse Large cell Lymphoma.

For decades, CHOP had remained King of treatment of diffuse large cell lymphoma
Elaborate combinations of chemotherapy drugs failed to improve on CHOP, until the targeting of CD20 by Rituxan.  And now with the arrival of the almighty powerful Ibrutinib, response rates seem to be overwhelming although not all seems to be complete Responses, at least not yet since analysis of data is still ongoing!

Wednesday, March 6, 2013

Mantle Cell Lymphoma

*In Mantle cell lymphoma, Rituxan-Bendamustine beats R-CHOP
with progression  free survival of 69 months vs 31 months and with better toxicity profile
except for skin erythematous lesion often seen with Bendamustine.

Friday, February 8, 2013

SUGGESTION OF TREATMENT OPTIONS IN PATIENTS WITH ACTIVATED B CELL LYMPHOMA AFTER FAILURE OF R-CHOP IF PATIENT IS A POOR CANDIDATE

IN Not transplant candidates:
The options are:

1.Revlimid+ Rituxan
2.Rev+RICE is being trial
3.Reduced Conditioning Allogeneic Transplant
4.R+Bendamustine
5.Whyndam  R-EPOCH,
6.Velcade + Chemotherapy in the ABC subtype

Nn CNS prophylaxis, with addition of RITUXAN,  the  incidence of CNs relapse has decreased.
Large Cell lymphoma with Bone Marrow infiltration in 50% of case it is because of small cell component is actually infiltrating which does impact the  prognosis considerably.  So, NO CNS prophylaxis supported.
-------------------------------------------------------------------------------------------------------
TREATMENT OPTIONS IN MANTLE CELL (SOX 11 MARKS AN INDOLENT COURSE)

1.R-HYPERCVAD (MODIFIED)
2.R-BENDAMUSTINE
3. 4 CYCLES OF R-DHAP (LYMA TRIAL), COULD BE  FOLLOWED BY REVELIMD OR RITUXAN MAINTENANCE
4.HIGH DOSE ARA-C CONTAINING REGIMEN
5 R-CHOP ALTERNATING WITH R-DHAP
6. IBRUTINIB
--------------------------------------------------------------------------------------------------

CLL, TREATMENT OPTION

1.RITUXAN-BENDAMUSTINE
2.FLUDARABINE, CYTOXAN, RITUXAN (FCR)
3.FOR AUTOIMMUNE HEMOLYTIC ANEMIA- PREDNISONE, IV IG , RITUXAN COMBINATION PRIOR TO STARTING THERAPY.
4. IBRUTINIB
5. LOW INTENSITY ALLO TRANSPLANT




CONTINUING MEDICAL EDUCATION CERTIFICATE


certifies that
Mutombo Kankonde, MD
2400 Trawood Drive
Suite 303
El Paso, TX 79936
has participated in the enduring material titled

Tailored Hematology: Challenging Community Cases in Non-Hodgkin Lymphoma

February 8, 2013
and is awarded 0.50  AMA PRA Category 1 Credit(s)™.
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
Certificate Number: 41862411 Cyndi Grimes
Cyndi Grimes
Director, Continuing Medical Education
Medscape, LLC




Friday, January 18, 2013

TALKING DE-ACETYLATION, PANOBINOSTAT

Panobinostat is a De-acetylator inhibitor for Histone, meaning that it paralyzes a few enzymes perinuclearly, therefore blocking Mitosis this way.
It has demonstrated Activity in Relapsed/Refractory Hodgkin's disease post transplantation. An area where it does not have much competition.   And here it is actually pretty good at achieving like most target therapies a 30% effectiveness and  with additional stable diseases.  A respectable effectiveness.
Now  it is being tried in Non Hodgkin's disease with Rituxan.  We will update you on this!